X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (29) 29
female (24) 24
adult (23) 23
male (23) 23
inflammatory bowel disease (20) 20
gastroenterology & hepatology (18) 18
middle aged (17) 17
adolescent (16) 16
index medicus (16) 16
gastroenterology and hepatology (14) 14
aged (13) 13
crohn's disease (13) 13
crohns-disease (13) 13
crohn disease - genetics (11) 11
infliximab (11) 11
inflammatory-bowel-disease (9) 9
genotype (8) 8
ulcerative colitis (8) 8
ulcerative-colitis (8) 8
young adult (8) 8
association (7) 7
inflammatory bowel diseases (7) 7
mutation (7) 7
nod2 signaling adaptor protein - genetics (7) 7
antibodies, monoclonal - therapeutic use (6) 6
care and treatment (6) 6
child (6) 6
cohort studies (6) 6
phenotype (6) 6
susceptibility (6) 6
aged, 80 and over (5) 5
case-control studies (5) 5
colitis, ulcerative - genetics (5) 5
genetic predisposition to disease (5) 5
genetics (5) 5
intestine (5) 5
medicine (5) 5
multidisciplinary sciences (5) 5
polymorphism, single nucleotide (5) 5
research article (5) 5
treatment outcome (5) 5
tumor necrosis factor-alpha - antagonists & inhibitors (5) 5
adalimumab (4) 4
analysis (4) 4
anti-inflammatory agents - therapeutic use (4) 4
colitis, ulcerative - drug therapy (4) 4
crohn disease - drug therapy (4) 4
crohn disease - pathology (4) 4
crohns disease (4) 4
digestive system diseases (4) 4
gastrointestinal agents - therapeutic use (4) 4
inflammatory bowel diseases - drug therapy (4) 4
medizin (4) 4
necrosis-factor-alpha (4) 4
patients (4) 4
polymorphism (4) 4
polymorphism, genetic (4) 4
predictors (4) 4
prognosis (4) 4
retrospective studies (4) 4
risk (4) 4
science (4) 4
therapy (4) 4
tumor necrosis factor (4) 4
colitis (3) 3
colitis, ulcerative - immunology (3) 3
colitis, ulcerative - pathology (3) 3
expression (3) 3
frameshift mutation (3) 3
gastroenterology (3) 3
gastrointestinal diseases (3) 3
gene polymorphism (3) 3
genetic aspects (3) 3
immunology (3) 3
immunosuppressive agents (3) 3
insertion mutation (3) 3
intestinal epithelial-cells (3) 3
intestinal obstruction - genetics (3) 3
logistic models (3) 3
monoclonal antibodies (3) 3
nod2 gene (3) 3
nod2 protein (3) 3
prospective studies (3) 3
receptors, interleukin - genetics (3) 3
rheumatoid-arthritis (3) 3
safety (3) 3
studies (3) 3
surgery (3) 3
time factors (3) 3
variants (3) 3
age (2) 2
antibodies (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antibodies, monoclonal, humanized - therapeutic use (2) 2
autoimmune diseases (2) 2
azathioprine (2) 2
bacteria - drug effects (2) 2
behavior (2) 2
biology and life sciences (2) 2
biomarkers - blood (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


07/2015, Frontiers of Gastrointestinal Research, ISBN 9783318054736, Volume 34, 6
The induction of autoimmunity due to the development of antinuclear antibodies, anti-double-stranded DNA antibodies or anti-histone antibodies is common in... 
Chapter
Book Chapter
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2014, Volume 9, Issue 6, p. e99293
Objective: Mucosal healing (MH) is an important treatment goal in patients with inflammatory bowel disease (IBD), but factors predicting MH under medical... 
SCORE | CROHNS-DISEASE | MULTIDISCIPLINARY SCIENCES | ULCERATIVE-COLITIS | VALIDATION | MARKERS | INFLIXIMAB THERAPY | FECAL CALPROTECTIN | REMISSION | Humans | Middle Aged | Gastrointestinal Agents - administration & dosage | Antibodies, Monoclonal - therapeutic use | Male | Intestinal Mucosa - drug effects | Young Adult | Antibodies, Monoclonal, Humanized - administration & dosage | Infliximab | Time Factors | Antibodies, Monoclonal, Humanized - pharmacology | Colonoscopy | Inflammatory Bowel Diseases - pathology | Adult | Female | Retrospective Studies | C-Reactive Protein - analysis | Drug Therapy, Combination | Child | Inflammatory Bowel Diseases - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Antibodies, Monoclonal - pharmacology | Hospitalization | Inflammatory Bowel Diseases - blood | Gastrointestinal Agents - pharmacology | Antibodies, Monoclonal - administration & dosage | Adolescent | Gastrointestinal Agents - therapeutic use | Inflammatory Bowel Diseases - surgery | Aged | Digestive System Surgical Procedures - utilization | Adalimumab | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Intestinal Mucosa - pathology | Viral antibodies | Care and treatment | Tumor necrosis factor | Gastrointestinal diseases | Analysis | Antibodies | Inflammatory bowel diseases | Mucosa | Medical services | Medical records | Ethics | Endoscopes | Intestine | Surgery | Gastroenterology | Endoscopy | Colon | Lesions | Drug dosages | Growth factors | Statistical analysis | Medical treatment | Tumor necrosis factor-α | Gene expression | Patients | Crohns disease | Inflammatory bowel disease | Medicine | Hospitals | Monoclonal antibodies | Healing
Journal Article
Pharmacoepidemiology and Drug Safety, ISSN 1053-8569, 07/2014, Volume 23, Issue 7, pp. 735 - 744
ABSTRACT Purpose We aimed to analyse malignancy rates and predictors for the development of malignancies in a large German inflammatory bowel disease (IBD)... 
skin cancer | malignancy | thiopurines | infliximab | lymphoma | azathioprine | melanoma | inflammatory bowel disease | adalimumab | pharmacoepidemiology | carcinoma | tumor | anti‐TNF antibodies | cancer | Carcinoma | Anti-TNF antibodies | Melanoma | Malignancy | Thiopurines | Lymphoma | Skin cancer | Inflammatory bowel disease | Pharmacoepidemiology | Infliximab | Tumor | Adalimumab | Azathioprine | Cancer | RHEUMATOID-ARTHRITIS | INFECTIONS | CROHNS-DISEASE | SAFETY | T-CELL LYMPHOMA | INDUCTION | anti-TNF antibodies | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | THERAPY | PHARMACOLOGY & PHARMACY | NONMELANOMA SKIN CANCERS | Azathioprine - administration & dosage | Azathioprine - therapeutic use | Neoplasms - etiology | Age Factors | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Young Adult | Anti-Inflammatory Agents - adverse effects | Time Factors | Aged, 80 and over | Anti-Inflammatory Agents - therapeutic use | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Retrospective Studies | Drug Therapy, Combination | Immunosuppressive Agents - administration & dosage | Inflammatory Bowel Diseases - drug therapy | Risk Factors | Proportional Hazards Models | Germany - epidemiology | Adolescent | Immunosuppressive Agents - adverse effects | Aged | Neoplasms - pathology | Azathioprine - adverse effects | Neoplasms - epidemiology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Cohort Studies | Viral antibodies | Care and treatment | Tumor necrosis factor | Gastrointestinal diseases | Antibodies | Lymphomas | Medical research | Immunoglobulins | Risk factors
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2014, Volume 9, Issue 11, p. e108503
Background: Very recently, a sub-analysis of genome-wide association scans revealed that the non-coding single nucleotide polymorphism (SNP) rs12212067 in the... 
TRANSCRIPTION FACTORS | HOMOZYGOSITY | INFLAMMATORY-BOWEL-DISEASE | METAANALYSIS | MULTIDISCIPLINARY SCIENCES | ULCERATIVE-COLITIS | SUSCEPTIBILITY | REGULATORY T-CELLS | RISK | FRAMESHIFT MUTATION | EXPRESSION | Crohn Disease - genetics | Prognosis | Humans | Middle Aged | Male | Nod2 Signaling Adaptor Protein - genetics | Young Adult | Crohn Disease - diagnosis | Aged, 80 and over | Adult | Female | Child | Severity of Illness Index | Genetic Predisposition to Disease | Genetic Association Studies | Introns | Genotype | Forkhead Transcription Factors - genetics | Homozygote | Phenotype | Adolescent | Alleles | Aged | Polymorphism, Single Nucleotide | Mutation | Forkhead Box Protein O3 | Genomics | Genetic aspects | Single nucleotide polymorphisms | Inflammatory bowel diseases | Transcription factors | Clinical trials | Inflammatory response | Genomes | Single-nucleotide polymorphism | Gene polymorphism | Immunosuppressive agents | Body mass index | Lymphocytes | Immunotherapy | Surgery | Cell cycle | Population | Tumor necrosis factor-TNF | Localization | Genotypes | NOD2 protein | FOXO3 protein | Aggressive behavior | Complications | Fistulae | Inflammation | Crohn's disease | Dentistry | Metabolism | Gene expression | Patients | Crohns disease | Inflammatory bowel disease | Medicine | Monocytes | Gene frequency | Body mass | Body size | Clinical medicine | Apoptosis | Polymorphism
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2015, Volume 10, Issue 8, p. e0135807
Background Currently, limited data of the outcome of inflammatory bowel disease (IBD) in patients after solid organ transplantation (SOT) are available. We... 
HEMOLYTIC-UREMIC SYNDROME | RISK-FACTORS | CROHNS-DISEASE | KIDNEY-TRANSPLANTATION | ORTHOTOPIC LIVER-TRANSPLANTATION | IMMUNOSUPPRESSION | MULTIDISCIPLINARY SCIENCES | ULCERATIVE-COLITIS | CASE SERIES | CLINICAL-COURSE | PRIMARY SCLEROSING CHOLANGITIS | Liver Transplantation - adverse effects | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Heart Transplantation - adverse effects | Male | Survival Rate | Treatment Outcome | Colitis, Ulcerative - pathology | Tacrolimus - therapeutic use | Immunosuppression | Crohn Disease - pathology | Crohn Disease - drug therapy | Adult | Female | Aged | Colitis, Ulcerative - drug therapy | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Kidney Transplantation - adverse effects | Heart | Care and treatment | Immunotherapy | Analysis | Patient outcomes | Liver | Transplantation | Liver cirrhosis | Ulcerative colitis | Therapy | Inflammatory bowel diseases | Nephrology | Transplants & implants | Syngeneic grafts | Clinical trials | Immunosuppressive agents | Intestine | Hepatology | Gastroenterology | Remission | Tumor necrosis factor-TNF | Liver diseases | Heart transplantation | Cholangitis | Disease control | Patients | Crohns disease | Inflammatory bowel disease | Heart rate | Medicine | Studies | Cirrhosis | Tacrolimus | Tumor necrosis factor | Surgeons | Liver transplantation | Kidney transplantation
Journal Article
Journal Article
Inflammatory Bowel Diseases, ISSN 1078-0998, 09/2011, Volume 17, Issue 9, pp. 1846 - 1854
Journal Article
Neuromodulation: Technology at the Neural Interface, ISSN 1094-7159, 08/2018, Volume 21, Issue 6, pp. 541 - 547
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 07/2010, Volume 45, Issue 7, pp. 721 - 731
We analyzed the prevalence of concomitant intestinal stenosis in patients with fistulizing Crohn's disease (CD), including the NOD2/CARD15 and IL23R genotype... 
Inflammatory bowel disease | NOD2/CARD15 |